A Phase 3 interventional study of Tirzepatide and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 118 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 26 in phase 3, and was the 2nd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,539 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 6th largest by enrollment of the 117 interventional ones that give a count, is the only one that started in 2019, is one of 51 in phase 3, and was the 3rd registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 2,539 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received once weekly (QW) subcutaneous (SC) doses of a matching placebo, administered over a period of 72 weeks. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the placebo dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Drug: Placebo
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 5 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Drug: Tirzepatide
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 10 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 10 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Drug: Tirzepatide
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 15 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 15 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Drug: Tirzepatide
Administered SC
Also known as: LY3298176
Administered SC
Percent Change From Baseline in Body Weight (Primary Treatment Period)
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period)
Percentage of participants who achieve greater than or equal to( ≥) 5% body weight reduction.
Time frame: Week 72
Change From Baseline in Body Weight (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 20
Percentage of Participants Who Achieve ≥10% Body Weight Reduction (Primary Treatment Period)
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time frame: Week 72
Percentage of Participants Who Achieve ≥15% Body Weight Reduction (Primary Treatment Period)
Percentage of participants who achieve ≥15% body weight reduction.
Time frame: Week 72
Percentage of Participants Who Achieve ≥20% Body Weight Reduction (Primary Treatment Period)
Percentage of participants who achieve ≥20% body weight reduction.
Time frame: Week 72
Change From Baseline in Waist Circumference (Primary Treatment Period)
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Change From Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 72 (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period
The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
Time frame: Baseline, Week 72
Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Percent change from baseline in triglycerides are reported as model-based estimate and Standard Error (SE) from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72 (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Percent Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Fasting Insulin is a test used to measure the amount of insulin in the body. Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization)
LS Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 176
Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 176 (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)
The percentage of participants with onset of Type 2 diabetes mellitus (T2DM), evaluated as time to onset of T2DM among those who had pre-diabetes at randomization, was reported. Time to onset of Type 2 diabetes mellitus was defined as the duration from the date of randomization to the adjudication committee-confirmed date of incident diabetes. Participants who did not experience the event were censored.
Time frame: Baseline through Week 176
Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 193 (Primary and Additional Treatment Periods + Safety Follow-up Period: Participants With Prediabetes at Randomization)
The percentage of participants with onset of Type 2 diabetes mellitus (T2DM), evaluated as time to onset of T2DM among those who had pre-diabetes at randomization, was reported. Time to onset of Type 2 diabetes mellitus was defined as the duration from the date of randomization to the adjudication committee-confirmed date of incident diabetes. Participants who did not experience the event were censored.
Time frame: Baseline through Week 193
Change From Baseline in Body Mass Index (BMI) - Primary Treatment Period
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Change From Baseline in Hemoglobin A1c (HbA1c) - Primary Treatment Period
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Change From Baseline in Fasting Glucose (Primary Treatment Period)
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Percent Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Percent Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Time frame: Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization)
Percentage of Participants Who Achieve ≥5% Body Weight Reduction.
Time frame: Week 176
Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score at Week 72 (Primary Treatment Period)
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcomes (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.
Time frame: Baseline, Week 72
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide (Primary Treatment Period)
PK: Steady State AUC of Tirzepatide. each participant will be assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose.
Time frame: Week 8, 16, and 36, at 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose
| Milestone | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Started | 643 | 630 | 636 | 630 |
| Received at least one dose of study drug | 643 | 630 | 636 | 630 |
| Participants with normoglycemia at randomization | 373 | 383 | 374 | 377 |
| Participants with prediabetes at randomization | 270 | 247 | 262 | 253 |
| Completed | 509 | 569 | 566 | 575 |
| Not completed | 134 | 61 | 70 | 55 |
| Withdrew: Adverse event | 6 | 4 | 8 | 6 |
| Withdrew: Death | 4 | 4 | 2 | 1 |
| Withdrew: Lost to follow-up | 41 | 17 | 15 | 13 |
| Withdrew: Other - as reported by the investigator | 21 | 7 | 6 | 12 |
| Withdrew: Physician decision | 0 | 0 | 3 | 1 |
| Withdrew: Pregnancy | 4 | 3 | 4 | 1 |
| Withdrew: Withdrawal by subject | 58 | 26 | 32 | 21 |
| Milestone | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Started | 213 | 227 | 229 | 232 |
| Completed | 182 | 201 | 211 | 217 |
| Not completed | 31 | 26 | 18 | 15 |
| Withdrew: Adverse event | 1 | 2 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 6 | 4 | 8 | 6 |
| Withdrew: Other - as reported by the investigator | 2 | 5 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
| Withdrew: Site closed | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 21 | 15 | 3 | 7 |
| Milestone | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Started | 478 | 543 | 548 | 560 |
| Entered from primary treatment period | 328 | 362 | 355 | 367 |
| Entered from additional treatment period | 150 | 181 | 193 | 193 |
| Completed | 421 | 508 | 514 | 518 |
| Not completed | 57 | 35 | 34 | 42 |
| Withdrew: Adverse event | 6 | 8 | 9 | 16 |
| Withdrew: Lost to follow-up | 4 | 4 | 10 | 3 |
| Withdrew: Missing weight at week 176 | 3 | 2 | 2 | 2 |
| Withdrew: Other - as reported by the investigator | 10 | 5 | 6 | 5 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 1 | 3 | 0 | 6 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 31 | 13 | 7 | 9 |
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| percent change | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight (Primary Treatment Period) | -2.4 ± 0.40 | -16.0 ± 0.39 | -21.4 ± 0.39 | -22.5 ± 0.39 |
Percentage of participants who achieve greater than or equal to( ≥) 5% body weight reduction.
| Percentage of Participants | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period) | 27.87 | 89.41 | 96.18 | 96.32 |
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| kilograms | Placebo | Pooled 10 mg/15 mg Tirzepatide |
|---|---|---|
| Change From Baseline in Body Weight (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period | -2.5 ± 0.22 | -13.2 ± 0.16 |
Percentage of Participants who Achieve ≥10% Body Weight Reduction
| Percentage of Participants | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥10% Body Weight Reduction (Primary Treatment Period) | 13.54 | 73.35 | 85.85 | 90.08 |
Percentage of participants who achieve ≥15% body weight reduction.
| Percentage of Participants | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥15% Body Weight Reduction (Primary Treatment Period) | 5.98 | 50.24 | 73.61 | 78.24 |
Percentage of participants who achieve ≥20% body weight reduction.
| Percentage of Participants | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥20% Body Weight Reduction (Primary Treatment Period) | 1.26 | 31.62 | 55.48 | 62.88 |
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| centimeters | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Waist Circumference (Primary Treatment Period) | -3.4 ± 0.42 | -14.6 ± 0.41 | -19.4 ± 0.41 | -19.9 ± 0.41 |
The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
| score on a scale | Placebo | Pooled 10 mg/15 mg Tirzepatide |
|---|---|---|
| Change From Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 72 (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period | 1.7 ± 0.27 | 4.0 ± 0.18 |
Percent change from baseline in triglycerides are reported as model-based estimate and Standard Error (SE) from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -6.3 ± 1.55 | -27.6 ± 0.66 |
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -1.11 ± 0.695 | -5.97 ± 0.364 |
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72 (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | 0.25 ± 0.757 | 7.92 ± 0.447 |
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| millimeter of mercury (mmHg) | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -1.3 ± 0.48 | -8.1 ± 0.27 |
Fasting Insulin is a test used to measure the amount of insulin in the body. Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -9.7 ± 2.60 | -46.9 ± 0.83 |
LS Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, treatment, time, treatment\*time (Type III sum of squares) in the model.
| percent change | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization) | -2.1 ± 0.78 | -15.4 ± 0.74 | -19.9 ± 0.72 | -22.9 ± 0.73 |
The percentage of participants with onset of Type 2 diabetes mellitus (T2DM), evaluated as time to onset of T2DM among those who had pre-diabetes at randomization, was reported. Time to onset of Type 2 diabetes mellitus was defined as the duration from the date of randomization to the adjudication committee-confirmed date of incident diabetes. Participants who did not experience the event were censored.
| Percentage of Participants | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 176 (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization) | 12.6 | 1.2 |
The percentage of participants with onset of Type 2 diabetes mellitus (T2DM), evaluated as time to onset of T2DM among those who had pre-diabetes at randomization, was reported. Time to onset of Type 2 diabetes mellitus was defined as the duration from the date of randomization to the adjudication committee-confirmed date of incident diabetes. Participants who did not experience the event were censored.
| Percentage of Participants | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 193 (Primary and Additional Treatment Periods + Safety Follow-up Period: Participants With Prediabetes at Randomization) | 13.7 | 2.4 |
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| kilograms per meter squared (kg/m^2) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) - Primary Treatment Period | -0.9 ± 0.16 | -5.9 ± 0.16 | -8.1 ± 0.16 | -8.6 ± 0.16 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| Percentage of HbA1c | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) - Primary Treatment Period | -0.07 ± 0.012 | -0.40 ± 0.012 | -0.49 ± 0.012 | -0.51 ± 0.012 |
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| milligram per deciliter (mg/dL) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Fasting Glucose (Primary Treatment Period) | 0.86 ± 0.514 | -7.73 ± 0.484 | -9.73 ± 0.486 | -10.55 ± 0.486 |
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -0.85 ± 1.076 | -6.86 ± 0.555 |
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -5.6 ± 1.55 | -27.6 ± 0.65 |
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
| percent change | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | 6.1 ± 2.65 | -5.9 ± 1.28 |
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
| mmHg | Placebo | Pooled 5 mg/10 mg/15 mg Tirzepatide |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period | -1.0 ± 0.35 | -5.3 ± 0.19 |
Percentage of Participants Who Achieve ≥5% Body Weight Reduction.
| Percentage of Participants | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization) | 24.62 | 90.61 | 91.92 | 94.78 |
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcomes (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.
| score on a scale | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score at Week 72 (Primary Treatment Period) | 10.1 ± 0.78 | 17.8 ± 0.73 | 20.7 ± 0.73 | 21.8 ± 0.73 |
PK: Steady State AUC of Tirzepatide. each participant will be assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose.
| nanograms*hours per milliliter (ng*h/mL) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide (Primary Treatment Period) | 88900 ± 20.2 | 177000 ± 22.0 | 266000 ± 20.4 |
Collected over Baseline up to Week 193. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 4/643 (0.6%) | 53/643 (8.2%) | 315/643 (49%) |
| 5 mg Tirzepatide | 4/630 (0.6%) | 57/630 (9%) | 443/630 (70.3%) |
| 10 mg Tirzepatide | 3/636 (0.5%) | 60/636 (9.4%) | 451/636 (70.9%) |
| 15 mg Tirzepatide | 2/630 (0.3%) | 50/630 (7.9%) | 429/630 (68.1%) |
| Event | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 3/643 | 3/630 | 6/636 | 7/630 |
| Covid-19 pneumoniaInfections and infestations | 4/643 | 7/630 | 4/636 | 3/630 |
| Covid-19Infections and infestations | 6/643 | 2/630 | 5/636 | 1/630 |
| AppendicitisInfections and infestations | 3/643 | 4/630 | 0/636 | 2/630 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/207 | 1/204 | 0/209 | 0/205 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/207 | 0/204 | 0/209 | 0/205 |
| Pancreatitis acuteGastrointestinal disorders | 0/643 | 3/630 | 0/636 | 0/630 |
| PneumoniaInfections and infestations | 0/643 | 3/630 | 1/636 | 0/630 |
| Cholecystitis acuteHepatobiliary disorders | 0/643 | 2/630 | 3/636 | 1/630 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/436 | 0/426 | 0/427 | 2/425 |
| Event | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 63/643 | 160/630 | 217/636 | 201/630 |
| DiarrhoeaGastrointestinal disorders | 51/643 | 128/630 | 143/636 | 149/630 |
| Covid-19Infections and infestations | 106/643 | 127/630 | 128/636 | 113/630 |
| ConstipationGastrointestinal disorders | 38/643 | 113/630 | 117/636 | 80/630 |
| VomitingGastrointestinal disorders | 12/643 | 58/630 | 74/636 | 81/630 |
| Decreased appetiteMetabolism and nutrition disorders | 22/643 | 60/630 | 75/636 | 55/630 |
| DyspepsiaGastrointestinal disorders | 31/643 | 59/630 | 64/636 | 74/630 |
| HeadacheNervous system disorders | 47/643 | 47/630 | 51/636 | 44/630 |
| Abdominal painGastrointestinal disorders | 24/643 | 38/630 | 38/636 | 33/630 |
| Urinary tract infectionInfections and infestations | 38/643 | 30/630 | 38/636 | 28/630 |
All randomized participants
| Age, Continuous(years) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Mean | 44.4 ± 12.5 | 45.6 ± 12.7 | 44.7 ± 12.4 | 44.9 ± 12.3 | 44.9 ± 12.5 |
| Sex: Female, Male(Participants) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Female | 436 | 426 | 427 | 425 | 1714 |
| Male | 207 | 204 | 209 | 205 | 825 |
| Race (NIH/OMB)(Participants) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 58 | 56 | 58 | 59 | 231 |
| Asian | 71 | 68 | 71 | 66 | 276 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 2 | 3 | 9 |
| Black or African American | 55 | 48 | 47 | 51 | 201 |
| White | 450 | 447 | 452 | 443 | 1792 |
| More than one race | 7 | 9 | 6 | 8 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Argentina | 93 | 90 | 90 | 91 | 364 |
| United States | 288 | 282 | 287 | 284 | 1141 |
| Japan | 33 | 30 | 30 | 31 | 124 |
| China | 7 | 9 | 7 | 7 | 30 |
| Taiwan | 15 | 12 | 15 | 16 | 58 |
| Brazil | 59 | 59 | 61 | 60 | 239 |
| Mexico | 108 | 110 | 107 | 108 | 433 |
| Russia | 32 | 29 | 30 | 27 | 118 |
| India | 8 | 9 | 9 | 6 | 32 |
| Baseline Body Weight(kilograms (kg)) | Placebo | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Total |
|---|---|---|---|---|---|
| Mean | 104.9 ± 21.37 | 102.88 ± 20.71 | 105.84 ± 23.32 | 105.59 ± 22.92 | 104.78 ± 22.12 |
Showing the first 100 of 118 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2019 to primary completion in Apr 2022, 27 months.
Results were first posted in Apr 2023, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 27 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide